Warfarin sodium

Modify Date: 2024-01-02 13:43:55

Warfarin sodium Structure
Warfarin sodium structure
 Common Name Warfarin sodium
CAS Number 129-06-6 Molecular Weight 330.310
Density 1.307g/cm3 Boiling Point 515.2ºC at 760mmHg
Molecular Formula C19H15NaO4 Melting Point N/A
MSDS N/A Flash Point 188.8ºC
Symbol GHS06 GHS08
GHS06, GHS08		 Signal Word Danger

 Use of Warfarin sodium


Warfarin sodium (WARF-42 sodium; Athrombine-K sodium) is a potent anticoagulant agent and a vitamin K1 recycling antagonist to deplete active vitamin K1. Warfarin sodium decreases blood coagulation and prevents blood clot formation by inhibiting vitamin K epoxide reductase[1][2].

 Names

Name warfarin-sodium
Synonym More Synonyms

 Warfarin sodium Biological Activity

Description Warfarin sodium (WARF-42 sodium; Athrombine-K sodium) is a potent anticoagulant agent and a vitamin K1 recycling antagonist to deplete active vitamin K1. Warfarin sodium decreases blood coagulation and prevents blood clot formation by inhibiting vitamin K epoxide reductase[1][2].
Related Catalog
Target

IC50: vitamin K1 recycling[1]

References

[1]. Ansell, J., et al., Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008. 133(6 Suppl): p. 160S-198S.

[2]. http://en.wikipedia.org/wiki/Warfarin

 Chemical & Physical Properties

Density 1.307g/cm3
Boiling Point 515.2ºC at 760mmHg
Molecular Formula C19H15NaO4
Molecular Weight 330.310
Flash Point 188.8ºC
Exact Mass 330.086792
PSA 70.34000
LogP 4.04780

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
GN4725000
CHEMICAL NAME :
Coumarin, 3-(alpha-acetonylbenzyl)-4-hydroxy-, sodium salt
CAS REGISTRY NUMBER :
129-06-6
LAST UPDATED :
199706
DATA ITEMS CITED :
38
MOLECULAR FORMULA :
C19-H15-O4.Na
MOLECULAR WEIGHT :
330.33
WISWESSER LINE NOTATION :
T66 BOVJ DYR&1V1 EQ &-NA-

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
300 ug/kg/2D
TOXIC EFFECTS :
Skin and Appendages - dermatitis, other (after systemic exposure)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
4 mg/kg
TOXIC EFFECTS :
Blood - changes in cell count (unspecified)
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
8700 ug/kg
TOXIC EFFECTS :
Blood - hemorrhage
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
25 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
374 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
160 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
200 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
200 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Blood - hemorrhage Skin and Appendages - hair
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
800 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
100 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Blood - hemorrhage Skin and Appendages - hair
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
182 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
543 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Bird - chicken
DOSE/DURATION :
200 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Blood - hemorrhage Skin and Appendages - hair
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
4280 ug/kg/11D-C
TOXIC EFFECTS :
Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
20 mg/kg/4D-I
TOXIC EFFECTS :
Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
9300 ug/kg/31D-C
TOXIC EFFECTS :
Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Bird - chicken
DOSE/DURATION :
1484 mg/kg/15W-C
TOXIC EFFECTS :
Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
160 mg/kg
SEX/DURATION :
female 1-17 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
21700 ug/kg
SEX/DURATION :
female 1-31 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - physical
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
26 mg/kg
SEX/DURATION :
female 1-38 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - skin and skin appendages Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
26 mg/kg
SEX/DURATION :
female 1-38 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - gastrointestinal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
37 mg/kg
SEX/DURATION :
female 1-35 week(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
12 mg/kg
SEX/DURATION :
female 1-35 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
12 mg/kg
SEX/DURATION :
female 1-35 week(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - Apgar score (human only)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
2450 mg/kg
SEX/DURATION :
female 7-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
2450 mg/kg
SEX/DURATION :
female 7-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - biochemical and metabolic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
1 mg/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
4 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
18 mg/kg
SEX/DURATION :
female 3-11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
18 mg/kg
SEX/DURATION :
female 3-11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - other measures of fertility Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
54 mg/kg
SEX/DURATION :
female 2-28 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility Reproductive - Effects on Newborn - stillbirth

MUTATION DATA

TYPE OF TEST :
Mutation test systems - not otherwise specified
TEST SYSTEM :
Rodent - mouse Leukocyte
DOSE/DURATION :
100 nmol/L
REFERENCE :
ONCOBS Oncology. (S. Karger AG, Postfach CH-4009 Basel, Switzerland) V.21- 1967- Volume(issue)/page/year: 28,232,1973 *** REVIEWS *** TOXICOLOGY REVIEW NYSJAM New York State Journal of Medicine. (Medical Soc. of the State of New York, POB 5405, Lake Success, NY 11042) V.1- 1901- Volume(issue)/page/year: 64,493,1964 TOXICOLOGY REVIEW JAMAAP JAMA, Journal of the American Medical Association. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1883- Volume(issue)/page/year: 203,223,1968 *** U.S. STANDARDS AND REGULATIONS *** EPA FIFRA 1988 PESTICIDE SUBJECT TO REGISTRATION OR RE-REGISTRATION FEREAC Federal Register. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) V.1- 1936- Volume(issue)/page/year: 54,7740,1989 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5375 No. of Facilities: 55 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 786 (estimated) No. of Female Employees: 522 (estimated)

 Safety Information

Symbol GHS06 GHS08
GHS06, GHS08
Signal Word Danger
Hazard Statements H300-H360
Precautionary Statements Missing Phrase - N15.00950417-P201-P280-P308 + P313
Hazard Codes T+:Verytoxic;
Risk Phrases R61;R28
Safety Phrases S53-S36/37/39-S45
RIDADR UN 1544 6.1/PG 2
WGK Germany 1
RTECS GN4725000
Packaging Group II
Hazard Class 6.1(a)
HS Code 2932209090

 Synthetic Route

Warfarin structure

Warfarin

CAS#:81-81-2

~%

Warfarin sodium Structure

Warfarin sodium

CAS#:129-06-6

Literature: WO2008/44246 A2, ; Page/Page column 6-8 ;

 Precursor & DownStream

Precursor  1

DownStream  1

 Customs

HS Code 2932209090
Summary 2932209090. other lactones. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

 Articles3

More Articles
Putative biomarker for phospholipid accumulation in cultured cells treated with phospholipidosis-inducing drugs: alteration of the phosphatidylinositol composition detected using high-performance liquid chromatography-tandem mass spectrometry.

J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 967 , 110-7, (2014)

We developed a high-performance liquid chromatography-tandem mass spectrometric method for phospholipid biomarker discovery and applied it to a cell-based assay system for the screening of phospholipi...

Warfarin pretreatment reduces cell death and MMP-9 activity in experimental intracerebral hemorrhage.

Transl. Stroke Res. 6(2) , 133-9, (2015)

Little is known about the pathophysiology of oral anticoagulation-associated intracerebral hemorrhage (OAC-ICH). We compared hematoma volume, number of terminal deoxynucleotidyl dUTP nick-end labeling...

Defining utility and predicting outcome of cadaveric lower extremity bypass grafts in patients with critical limb ischemia.

J. Vasc. Surg. 60(6) , 1554-64, (2014)

Despite poor long-term patency, acceptable limb salvage has been reported with cryopreserved saphenous vein bypass (CVB) for various indications. However, utility of CVB in patients with critical limb...

 Synonyms

UNII:6153CWM0CL
3-(A-ACETONYLBENZYL)-4-HYDROXYCOUMARIN SODIUM SALT
3-(α-Acetonylbenzyl)-4-hydroxycoumarin Sodiuim Salt (contains Isopropyl Alcohol)
WARFARIN SODIUM, EP STANDARD
4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one sodium salt
panwarfin
4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin Sodium Salt (contains Isopropyl Alcohol)
EINECS 204-929-4
3-(Alpha-Acetonylbenzyl)-4-Hydroxycoumarin Sodiuim Salt
2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, sodium salt (1:1)
3-(α-ACETONYLBENZYL)-4-HYDROXYCOUMARIN SODIUM SALT
3-(A-ACETONYLBENZYL)-4-HYDROXYCOUMARIN
zoocoumarin-sodium
warfilone
athrombin
WARFARIN SODIUMLINE
Warfarin sodium
Sodium 2-oxo-3-(3-oxo-1-phenylbutyl)-2H-chromen-4-olate
WARFARIN SODIUM, (CONTAINS ISOPROPYL ALCOHOL)
3-(ALPHA-ACETONYLBENZYL)-4-HYDROXYCOUMARIN SODIUM CLATHRATE
warfarin sodium salt
waran
coumadin
Warfarinsodium
tintorane
MFCD00083223
rac-sodium 2-oxo-3-[(1R)-3-oxo-1-phenylbutyl]-2H-1-benzopyran-4-olate
Warfarin SodiuM (contains Isopropyl Alcohol)
varfine
3-(A-ACETONYLBENZYL)-4-HYDROXYCOUMARIN SODIUM
warcoumin
sodium 2-oxo-3-[(RS)-3-oxo-1-phenylbutyl]-2H-chromen-4-olate
marevan
Top Suppliers:I want be here

Get all suppliers and price by the below link:

Warfarin sodium suppliers

Price: ￥68/5g

Reference only. check more Warfarin sodium price

Related Compounds: More...
warfarin sodium
51821-81-9
D-Warfarin sodium
36508-91-5
Warfarin Sodium Clatharate
67430-45-9
Warfarin sodium impurity A [EP]
15156-56-6
Warfarin
81-81-2
WARFARIN RELATED COMPOUND A (50 MG) (3-(O-HYDROXYPHENYL)-5-PHENYL-2-CYCLOHEXEN-1-ONE)
37209-23-7
warfarin-deanol
3324-63-8
calcium,sodium,propanoate,diacetate
89087-69-4
Aminonaphtylsulphonate sodium
30605-57-3
N-[1-(2,5-dimethylfuran-3-carbonyl)piperidin-4-yl]-N-methylpyridin-2-amine
2741890-07-1
3-Fluoro-1-[6-(trifluoromethyl)pyrimidin-4-yl]pyrrolidine-3-carboxamide
2741912-65-0
6-Chloro-3-ethyl-8-methyl-3,4-dihydroquinazolin-4-one
2741947-55-5
4-((Cyclohexylamino)methyl)benzoic acid hydrochloride
1158522-08-7
1-[(2,4-Dichlorophenyl)methyl]-N-(1,1-dimethylethyl)-2-methyl-1H-indole-3-methanamine
940364-43-2
2,4-Dimethyl-6-[4-({4-[4-(pyridin-2-yl)piperazin-1-yl]but-2-yn-1-yl}oxy)piperidin-1-yl]pyrimidine
2640963-65-9
2-Cyclopropyl-4-({5-phenylmethanesulfonyl-octahydropyrrolo[3,4-c]pyrrol-2-yl}methyl)-1,3-thiazole
2549042-31-9
2-Methoxy-6-(pyrazol-1-yl)-benzonitrile
134104-43-1
3-(2-(3-Bromopropoxy)acetyl)oxazolidin-2-one
1636884-96-2
(5-Bromo-2-methoxyphenyl)(3,3-difluoropyrrolidin-1-yl)methanone
2814329-23-0
Chemsrc provides Warfarin sodium(CAS#:129-06-6) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of Warfarin sodium are included as well.>> amp version: Warfarin sodium

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved